Topics of Interest

Reply to FDA regarding the use of power morcellators for fibroids

Jeffrey Shuren, M.D., J.D., the Director of the Center for Device and Radiological Health at the Food and Drug Administration, replied to an open letter from the Leiomyoma Morcellation Review Group.  You can read the original open letter here, and view Dr. Shuren’s reply in the images below.

from FDA 1from FDA 2

The Leiomyoma Morcellation Review Group sent the following letter to the FDA in response:

Dear Dr. Shuren,

Thank you for your response to our letter and for your invitation to continue the dialog regarding the FDA’s restriction on the use of the morcellator for the majority of women with uterine fibroids.  We respect the FDA’s difficult position in this matter, especially considering the adverse publicity and pressure  generated by Dr. Reed’s husband. As responsible physicians and women’s health-care advocates we think that women who need treatment for uterine fibroids, as with all patients, deserve to make treatment decisions based on the best information available.  We know that this is also something that the FDA believes as well.  We would like to make the following comments:

1) As we are sure you are aware, a recent publication from the Michigan Surgical Quality Collaboration showed that the rate of laparoscopic hysterectomies decreased and the rate of abdominal hysterectomies increased following the FDA’s restrictive policy on morcellation, and there was an associated concomitant increase in major surgical complications and 30-day readmissions to the hospital (Harris).  This increase in morbidity was anticipated by the decision analysis published by Siedhoff and colleagues.  Unintentionally, the FDA is compromising the health of some women.  Our concerns regarding higher surgical morbidity associated with increased use of laparotomy for women needing surgical treatment for fibroids drove our decision to prepare our letter questioning the FDA’s guidance regarding morcellation.  Unfortunately, our concerns are now validated by published data.

2) In our letter to the FDA and our commentary published in Obstetrics and Gynecology, we did “challenge” your methodology and calculation of the prevalence of leiomyosarcoma among women having surgery for presumed fibroids, as well as the impact of electro-mechanical morcellation on survival.  We are very concerned that your researcher did not carefully consider all of the published data available at that time.  We are also concerned that the FDA analysis was reported to be performed by a close friend of Dr. Noorchashm and that this conflict of interest was not disclosed during the hearing.

The Kaiser study that you cite is only one of many recent attempts to determine the prevalence of LMS among women having surgery for uterine fibroids.  In a further analysis, we added the women from the Bojahr study cited by us and the Raines-Bennet study cited by you and re-calculated our meta-analysis.  The rate of LMS then becomes 1:1924 or 0.052% and essentially no different from our original calculation.

3) In the Kaiser study you cite, our concern is that it appears that you incorrectly state that “the adjusted risk ratio for death at one year for power morcellated uteri was significantly greater compared to uteri that were not morcellated”.  In fact, there was no difference in one year survival in these groups of women, as noted in the abstract and indicated in Figure 3.    The only statistically significant finding in that analysis was the one-year comparison of women with any type of morcellation compared with no morcellation, suggesting that power morcellation is not the determining factor.  The analysis also showed no increased mortality at  2 or 3 years, consistent with an aggressive disease that has early spread by the hematogenous route.

Additionally, the FDA did not carefully considered the published literature. Indeed, the data used to determine that laparoscopic power morcellation “significantly worsening the patient’s long-term survival” has been criticized by us and others for being of poor quality characterized by heterogeneous referral populations, small numbers and suboptimal quantitative analysis.

Furthermore, since the vast majority of cases analyzed in the literature were morcellation procedures performed using a scalpel via either the vaginal or mini-laparotomy routes, it would seem reasonable to restrict of vaginal and mini-lap morcellation in addition to electro-mechanical morcellation.  Such a restriction would essentially limit surgical options for women with fibroids to total abdominal hysterectomy, a position that would be called into question by most women and their gynecologists.

We respect the concerns of the FDA staff.  However, the FDA’s  decision  to place a boxed warning, albeit intended to protect women and to make them aware of risks,  has in fact reduced treatment options for women, paradoxically increasing the risks associated with surgery for uterine fibroids. Although we are not questioning your intentions, your agency’s actions do not appear consistent with your mission to ensure the safety and health of all women.

4) While we agree that a registry might clarify the prevalence of LMS and the influence of morcellation on survival, the registry would need to be mandatory for all US women with uterine LMS.  With such a rare condition, anything less would be subject to significant selection and reporting bias.   We are aware that a registry of women with leiomyomas is currently being developed through funding from PCORI and that this will provide important prospective data.  It will be essential to have appropriate funding for an LMS registry as well.  We sincerely hope that the FDA is discussing this need with your sister federal agencies.

Women and their physicians look to the FDA for guidance on issues that impact public health and safety. We do not feel that women have been properly served by the FDA’s current morcellation advisory.  We request that the FDA reconsider the currently available data and re-evaluate the restrictions on the use of the electro-mechanical morcellator for the majority of women with uterine fibroids.  We welcome the opportunity to talk to you about these issues and would be willing to send a group to Washington for further discussion if you wish.  We are confident that the FDA shares with our group a common concern for the health and safety of all women with leiomyomas. Our goal is to find a way forward that will provide an appropriate and reasonable approach to uterine leiomyoma treatment and medical care.

Thank you for your consideration,

William H. Parker, MD, Santa Monica-UCLA Medical Center

Andrew M. Kaunitz, MD , University of Florida College of Medicine–Jacksonville

Elizabeth Pritts, MD, Middleton, WI

David Olive, MD, Middleton, WI

Eva Chalas, MD, FACOG, FACS, Winthrop-University Hospital, Mineola, NY

Daniel L. Clarke-Pearson, MD, UNC-Chapel Hill

Jonathan S Berek, MD, MMS, Stanford University School of Medicine

Barbara Goff, MD, University of Washington, Seattle, WA

Robert Bristow, MD, UC Irvine School of Medicine

Robin Farias-Eisner, MD, David Geffen School of Medicine at UCLA

Amanda Nickles Fader, MD, Johns Hopkins Medicine

G Larry Maxwell, MD, FACOG, COL(ret) U.S. Army, Inova Fairfax Hospital

Scott C Goodwin, MD, University of California, Irvine

Susan Love, MD, Dr. Susan Love Research Foundation, Los Angeles, California

William E Gibbons, MD, Baylor College of Medicine

Leland J. Foshag, M.D., FACS, John Wayne Cancer Institute, Santa Monica, California

Phyllis C. Leppert, MD, PhD, Duke University School of Medicine

Charles W. Nager, MD, UC San Diego Health System

Judy Norsigian, Our Bodies, Ourselves, Boston, Mass

Timothy Johnson, MD, University of Michigan

David S. Guzick, MD, PhD, University of Florida

Anton J. Bilchik, MD, PhD, FACS, John Wayne Cancer Institute, Santa Monica, California

Hugh Taylor, MD, Yale School of Medicine

Richard J. Paulson, MD, Keck School of Medicine, University of Southern California

Professor Cindy Farquhar, University of Auckland, NZ

Sawsan As-Sanie, MD MPH, University of Michigan

Linda D. Bradley, MD, Cleveland Clinic

Stacey A. Scheib, MD, Johns Hopkins Hospital

Carla Dionne, MPH, MBA, National Uterine Fibroid Foundation

Laurel W. Rice, MD , University of Wisconsin-Madison School of Medicine and Public Health

Alison Jacoby, MD, University of California, San Francisco

Charles Ascher-Walsh, MD, Mt. Sinai School of Medicine

G. David Adamson, MD, Stanford University School of Medicine

Matthew Siedhoff, MD MSCR, University of North Carolina at Chapel Hill

Robert Israel, M.D, Keck School of Medicine, University of Southern California

Marie Fidela Paraiso, MD, Cleveland Clinic

Michael M. Frumovitz, M. D., M.P.H., FACOG, FACS, The University of Texas MD Anderson Cancer Center

Guy I. Benrubi, M.D., University of Florida College of Medicine – Jacksonville

Steven S. Raman, MD, David Geffen School of Medicine at UCLA

Rosanne M Kho MD, Columbia University Medical Center

John R Lurain, MD, Northwestern University Feinberg School of Medicine

Ayman Al-Hendy  MD PhD FRCSC FACOG CCRP, Medical College of Georgia

Ted L. Anderson, M.D., Ph.D., Vanderbilt University School of Medicine

R. Kevin Reynolds, MD, FACS, FACOG, University of Michigan

John DeLancey, MD, University of Michigan Health System


Disclaimer: The ideas, procedures and suggestions contained on this web site are not intended as a substitute for consulting with your physician. All matters regarding your health require medical supervision.

Fibroid Doctor William H. Parker

Dr. William H. Parker is a board-certified Fellow in the American College of Obstetricians and Gynecologists. Dr. Parker is an internationally recognized expert in fibroid surgery and research. Based in San Diego, California, he is considered one of the best fibroid surgeons for abdominal and laparoscopic myomectomy in the United States and abroad. He has been chosen for Best Doctors in America and Top Doctors every year beginning in the late 90's.

Free Email Updates

Powered by Google FeedBurner : Receive free updates right to your inbox every time new content is added to this website.

Schedule an Appointment Today!
Read Dr. Parker's Blog

Blog Categories